Clinical trials for Lymphoma
93 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2
Lymphoma
CLL & Richter's syndrome
Acute leukemia
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
Multiple myeloma
#NCT04935684
Required histologic types
B cell lymphoma
T cell lymphoma
Hodgkin lymphoma
CLL (Chronic Lymphocytic Leukemia)
Symptomatic multiple myeloma
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Allogeneic stem cell transplant
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
CHU de Clermont-Ferrand
Phase 2
Lymphoma
CLL & Richter's syndrome
#NCT07221500
#2025-521088-10-00
Required histologic types
B cell lymphoma
CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Targeted therapy
Excluded previous treatments
Car-T
1 recruiting site
Nurix Therapeutics, Inc.
Phase 2
Lymphoma
#NCT04844866
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Primary mediastinal lymphoma
Follicular lymphoma
Indolent transformed lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
1
Required previous treatments
Chemotherapy
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive
Car-T
5 recruiting sites
Miltenyi Biomedicine GmbH
Phase 2
Lymphoma
#NCT06547866
Required histologic types
B cell lymphoma
Required histologic sub types
Waldenström lymphoma
Required central nervous system lesions
None
Treated / Controled
Required renal function statuses
> 60 ml/min
50-60 ml/min
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
French Innovative Leukemia Organisation (FILO)
Phase 2
Lymphoma
#NCT06806033
#2024-516791-15-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Indolent transformed lymphoma
Required central nervous system lesions
None
Treated / Controled
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
Bispecific T-cell engager antibodies
Allogeneic stem cell transplant
4 recruiting sites
Hoffmann-La Roche
Phase 2
Lymphoma
#NCT06931652
#2023-505834-84-00
Required histologic types
B cell lymphoma
Required histologic sub types
Primary cerebral lymphoma
Required central nervous system lesions
Actives
Required renal function statuses
> 60 ml/min
50-60 ml/min
30-50 ml/min
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Chemotherapy
Excluded previous treatments
Systemic Treatment-Naive
Bispecific T-cell engager antibodies
Allogeneic stem cell transplant
6 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2
Lymphoma
#NCT06534437
#2024-513098-31-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Indolent transformed lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
2
3 or more
Required previous treatments
Chemotherapy
Bispecific T-cell engager antibodies
Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive
7 recruiting sites
Ryvu Therapeutics SA
Phase 2
Lymphoma
#NCT04728893
#2023-504931-42-00
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Follicular lymphoma
Marginal zone lymphoma
Required central nervous system lesions
None
Treated / Controled
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Chemotherapy
Targeted therapy
Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Merck Sharp & Dohme LLC
Phase 2
Lymphoma
#NCT06482684
#2022-502405-15-01
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required disease stage
Early (stage I and II)
Disseminated (stage III and IV)
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
2 recruiting sites
Ludwig-Maximilians - Université de Munich
Phase 2
Lymphoma
#NCT06588478
#2024-515689-15-01
Required histologic types
B cell lymphoma
Required histologic sub types
Lymphocytic lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
6 recruiting sites
Loxo Oncology